-
3
-
-
84868587857
-
Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo
-
Simpkins F, Hevia-Paez P, Sun J, et al: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18: 5911-5923, 2012.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5911-5923
-
-
Simpkins, F.1
Hevia-Paez, P.2
Sun, J.3
-
4
-
-
84886098299
-
Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer
-
Argenta PA, Um I, Kay C, et al: Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol 131: 368-373, 2013.
-
(2013)
Gynecol Oncol
, vol.131
, pp. 368-373
-
-
Argenta, P.A.1
Um, I.2
Kay, C.3
-
5
-
-
84864477585
-
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells
-
Badia E, Docquier A, Busson M, et al: Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. J Steroid Biochem Mol Biol 132: 176-185, 2012.
-
(2012)
J Steroid Biochem Mol Biol
, vol.132
, pp. 176-185
-
-
Badia, E.1
Docquier, A.2
Busson, M.3
-
6
-
-
84866132321
-
Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer
-
Bossard C, Busson M, Vindrieux D, et al: Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 7: e44787, 2012.
-
(2012)
PLoS One
, vol.7
-
-
Bossard, C.1
Busson, M.2
Vindrieux, D.3
-
7
-
-
80052713086
-
Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival
-
Halon A, Materna V, Drag-Zalesinska M, et al: Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 17: 511-518, 2011.
-
(2011)
Pathol Oncol Res
, vol.17
, pp. 511-518
-
-
Halon, A.1
Materna, V.2
Drag-Zalesinska, M.3
-
8
-
-
78649496224
-
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature
-
Kothari R, Argenta P, Fowler J, Carter J and Shimp W: Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature. Arch Oncol 18: 32-35, 2010.
-
(2010)
Arch Oncol
, vol.18
, pp. 32-35
-
-
Kothari, R.1
Argenta, P.2
Fowler, J.3
Carter, J.4
Shimp, W.5
-
9
-
-
34250708027
-
Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients
-
DOI 10.1158/1078-0432.CCR-06-2878
-
Smyth JF, Gourley C, Walker G, et al: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622, 2007. (Pubitemid 46955124)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.12
, pp. 3617-3622
-
-
Smyth, J.F.1
Gourley, C.2
Walker, G.3
MacKean, M.J.4
Stevenson, A.5
Williams, A.R.W.6
Al, N.A.7
Rye, T.8
Rye, R.9
Stewart, M.10
McCurdy, J.11
Mano, M.12
Reed, N.13
McMahon, T.14
Vasey, P.15
Gabra, H.16
Langdon, S.P.17
-
10
-
-
84873430440
-
Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models
-
Park MA, Hwang KA, Lee HR, Yi BR, Jeung EB and Choi KC: Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models. Toxicology 305: 41-48, 2013.
-
(2013)
Toxicology
, vol.305
, pp. 41-48
-
-
Park, M.A.1
Hwang, K.A.2
Lee, H.R.3
Yi, B.R.4
Jeung, E.B.5
Choi, K.C.6
-
11
-
-
84883428665
-
Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression
-
Wang L, Wang G, Yang D, et al: Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. Mol Med Rep 8: 1279-1285, 2013.
-
(2013)
Mol Med Rep
, vol.8
, pp. 1279-1285
-
-
Wang, L.1
Wang, G.2
Yang, D.3
-
12
-
-
84921366824
-
Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro
-
[Epub ahead of print]
-
Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro. Breast Cancer 2013 [Epub ahead of print].
-
(2013)
Breast Cancer
-
-
Jiang, D.1
Wang, X.2
Liu, X.3
Li, F.4
-
13
-
-
28544433273
-
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
-
DOI 10.1158/1078-0432.CCR-05-1270
-
Psyrri A, Bamias A, Yu Z, et al: Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 11: 8384-8390, 2005. (Pubitemid 41746951)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.23
, pp. 8384-8390
-
-
Psyrri, A.1
Bamias, A.2
Yu, Z.3
Weinberger, P.M.4
Kassar, M.5
Markakis, S.6
Kowalski, D.7
Efstathiou, E.8
Camp, R.L.9
Rimm, D.L.10
Dimopoulos, M.A.11
-
14
-
-
0034759710
-
Kip1 epithelial ovarian cancer
-
DOI 10.1006/gyno.2001.6376
-
Hurteau JA, Allison BM, Brutkiewicz SA, et al: Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in epithelial ovarian cancer. Gynecol Oncol 83: 292-298, 2001. (Pubitemid 33033069)
-
(2001)
Gynecologic Oncology
, vol.83
, Issue.2
, pp. 292-298
-
-
Hurteau, J.A.1
Allison, B.M.2
Brutkiewicz, S.A.3
Goebl, M.G.4
Heilman, D.K.5
Bigsby, R.M.6
Harrington, M.A.7
-
15
-
-
18744407590
-
A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance
-
DOI 10.1073/pnas.0502256102
-
Xing D and Orsulic S: A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathwaytargeted therapy and tumor resistance. Proc Natl Acad Sci USA 102: 6936-6941, 2005. (Pubitemid 40675420)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.19
, pp. 6936-6941
-
-
Xing, D.1
Orsulic, S.2
-
16
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
-
17
-
-
84874271542
-
Expression of c-Src and phospho-Src in epithelial ovarian carcinoma
-
Huang YW, Chen C, Xu MM, Li JD, Xiao J and Zhu XF: Expression of c-Src and phospho-Src in epithelial ovarian carcinoma. Mol Cell Biochem 376: 73-79, 2013.
-
(2013)
Mol Cell Biochem
, vol.376
, pp. 73-79
-
-
Huang, Y.W.1
Chen, C.2
Xu, M.M.3
Li, J.D.4
Xiao, J.5
Zhu, X.F.6
-
18
-
-
79953319793
-
Functional roles of Src and Fgr in ovarian carcinoma
-
Kim HS, Han HD, Armaiz-Pena GN, et al: Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17: 1713-1721, 2011.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1713-1721
-
-
Kim, H.S.1
Han, H.D.2
Armaiz-Pena, G.N.3
-
20
-
-
84859889324
-
EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation
-
Zhao Y, Li X, Sun X, Zhang Y and Ren H: EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation. Cell Physiol Biochem 29: 341-352, 2012.
-
(2012)
Cell Physiol Biochem
, vol.29
, pp. 341-352
-
-
Zhao, Y.1
Li, X.2
Sun, X.3
Zhang, Y.4
Ren, H.5
-
21
-
-
84869495012
-
Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells
-
Castoria G, Giovannelli P, Lombardi M, et al: Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 31: 4868-4877, 2012.
-
(2012)
Oncogene
, vol.31
, pp. 4868-4877
-
-
Castoria, G.1
Giovannelli, P.2
Lombardi, M.3
-
22
-
-
33846268807
-
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
-
DOI 10.1016/j.cell.2006.11.049, PII S0092867407000037
-
Chu I, Sun J, Arnaout A, et al: p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128: 281-294, 2007. (Pubitemid 46123510)
-
(2007)
Cell
, vol.128
, Issue.2
, pp. 281-294
-
-
Chu, I.1
Sun, J.2
Arnaout, A.3
Kahn, H.4
Hanna, W.5
Narod, S.6
Sun, P.7
Tan, C.-K.8
Hengst, L.9
Slingerland, J.10
-
23
-
-
84876207386
-
The role of hormonal factors and endocrine therapy in ovarian cancer
-
Serkies K, Sinacki M and Jassem J: The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp Oncol 17: 14-19, 2013.
-
(2013)
Contemp Oncol
, vol.17
, pp. 14-19
-
-
Serkies, K.1
Sinacki, M.2
Jassem, J.3
-
24
-
-
84874980133
-
Stem cells: Anatomy of an ovarian cancer
-
Brenton JD and Stingl J: Stem cells: anatomy of an ovarian cancer. Nature 495: 183-184, 2013.
-
(2013)
Nature
, vol.495
, pp. 183-184
-
-
Brenton, J.D.1
Stingl, J.2
-
25
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98
-
DOI 10.1200/JCO.2006.08.8617
-
Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492, 2007. (Pubitemid 350002953)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.5
, pp. 486-492
-
-
Coates, A.S.1
Keshaviah, A.2
Thurlimann, B.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Colleoni, M.10
Lang, I.11
Del, M.L.12
Smith, I.13
Chirgwin, J.14
Nogaret, J.-M.15
Pienkowski, T.16
Wardley, A.17
Jakobsen, E.H.18
Price, K.N.19
Goldhirsch, A.20
more..
-
26
-
-
81255157751
-
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up
-
Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12: 1101-1108, 2011.
-
(2011)
Lancet Oncol
, vol.12
, pp. 1101-1108
-
-
Regan, M.M.1
Neven, P.2
Giobbie-Hurder, A.3
-
27
-
-
79955863530
-
Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src
-
Jung J, Kim HY, Kim M, Sohn K, Kim M and Lee K: Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene 30: 2264-2274, 2011.
-
(2011)
Oncogene
, vol.30
, pp. 2264-2274
-
-
Jung, J.1
Kim, H.Y.2
Kim, M.3
Sohn, K.4
Kim, M.5
Lee, K.6
-
28
-
-
68049094943
-
Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells
-
Hui AY, Meens JA, Schick C, et al: Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells. J Cell Biochem 107: 1168-1181, 2009.
-
(2009)
J Cell Biochem
, vol.107
, pp. 1168-1181
-
-
Hui, A.Y.1
Meens, J.A.2
Schick, C.3
-
29
-
-
77953405023
-
ErbB-inhibitory protein: A modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells
-
Nautiyal J, Yu Y, Aboukameel A, et al: ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther 9: 1503-1514, 2010.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1503-1514
-
-
Nautiyal, J.1
Yu, Y.2
Aboukameel, A.3
-
30
-
-
77952114407
-
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
-
Moulder S, Yan K, Huang F, et al: Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9: 1120-1127, 2010.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1120-1127
-
-
Moulder, S.1
Yan, K.2
Huang, F.3
-
31
-
-
84855748821
-
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
-
Gucalp A, Sparano JA, Caravelli J, et al: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11: 306-311, 2011.
-
(2011)
Clin Breast Cancer
, vol.11
, pp. 306-311
-
-
Gucalp, A.1
Sparano, J.A.2
Caravelli, J.3
-
32
-
-
77955760833
-
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer
-
Arcaroli JJ, Touban BM, Tan AC, et al: Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res 16: 4165-4177, 2010.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4165-4177
-
-
Arcaroli, J.J.1
Touban, B.M.2
Tan, A.C.3
-
33
-
-
84880376355
-
Emerging regulation and functions of autophagy
-
Boya P, Reggiori F and Codogno P: Emerging regulation and functions of autophagy. Nat Cell Biol 15: 713-720, 2013.
-
(2013)
Nat Cell Biol
, vol.15
, pp. 713-720
-
-
Boya, P.1
Reggiori, F.2
Codogno, P.3
-
34
-
-
84877628647
-
Autophagy in human health and disease
-
Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.
-
(2013)
N Engl J Med
, vol.368
, pp. 651-662
-
-
Choi, A.M.1
Ryter, S.W.2
Levine, B.3
|